Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been recently diagnosed with a solid tumour cancer and have not yet received any systemic (whole-body) cancer treatment
- People whose doctors have planned a first-line standard treatment using one or two immune checkpoint inhibitor medicines, with or without chemotherapy (including people receiving treatment before surgery)
- People aged 18 or older
- People whose doctors estimate they have a life expectancy of at least 3 months
- People who are considered generally well and active, with an ECOG performance score of 0 or 1 — meaning they are either fully active or have only minor restrictions on physical activity (confirm with trial site)
- People who are willing and able to attend hospital visits and scheduled follow-up appointments for the full length of the study
- Women who could potentially become pregnant may be eligible if they are using a highly effective form of contraception, have a negative pregnancy test within 7 days before starting the study treatment, and are not breastfeeding at the time of starting the trial
- Women who cannot become pregnant may be eligible if they meet specific criteria, such as being post-menopausal or having had a surgical procedure such as removal of the uterus, both ovaries, or both fallopian tubes (tubal ligation alone does not qualify)
Who may not be able to join:
- People who have received chemotherapy, steroid medicines (glucocorticoids), or immune-modifying medicines — such as low-dose methotrexate, TNF-alpha inhibitors, or similar drugs — in the past 3 months (note: skin-applied steroid creams and hormone replacement therapy are acceptable)
- People who are currently taking or planning to take certain supplements that affect cell energy production, such as coenzyme Q10, NAD+ boosters (for example, nicotinamide riboside or nicotinamide mononucleotide), or L-carnitine
- People who have had radiotherapy to the chest area (mediastinum) or to other areas where, in the treating doctor's judgement, a large blood vessel would have been significantly exposed to radiation
- People with a known HIV infection (HIV testing is not required as part of this trial)
- People who have previously received a transplanted solid organ or bone marrow/blood stem cell transplant
- People with any other medical condition that the trial investigators consider would affect the safety of the person or the reliability of the study results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fabian Acker, MD, Goethe Universität
Phone: 06963015970
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in the composition of circulating lymphocytes
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.